Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

RECURSION PHARMACEUTICALS, INC.

(RXRX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Recursion Pharmaceuticals Sets Drug-Discovery Pact With Roche, Genentech

12/07/2021 | 08:37am EST

By Colin Kellaher

Recursion Pharmaceuticals Inc. on Tuesday said it formed a drug-discovery collaboration with Roche Holding AG and its Genentech unit that is potentially worth several billion dollars to the clinical-stage biotechnology company.

Recursion said it will work with the R&D units of both Roche and Genentech to use its Recursion Operating System to more rapidly identify novel targets and advance medicines in key areas of neuroscience, as well as in an oncology indication.

The Salt Lake City, Utah, company said it will receive an upfront payment of $150 million, adding that Roche and Genentech may initiate up to 40 programs, each of which could yield more than $300 million in development, commercialization and sales milestones, along with royalties on sales.

Recursion reported cash, cash equivalents and investments of $578.9 million as of Sept. 30.

Recursion said the companies will use insights generated from the collaboration's maps of human cellular biology to find and develop medicines against novel targets in neuroscience and the oncology indication for up to a decade or longer, adding that Recursion's other programs already underway in oncology or neuroscience aren't part of the collaboration.

Shares of Recursion, which closed Monday at $18.48, were recently up 5.5% in premarket trading.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

12-07-21 0837ET

Stocks mentioned in the article
ChangeLast1st jan.
RECURSION PHARMACEUTICALS, INC. -5.42% 10.45 Delayed Quote.-35.32%
ROCHE HOLDING AG 1.58% 354.6 Delayed Quote.-7.91%
All news about RECURSION PHARMACEUTICALS, INC.
01/18INSIDER SELL : Recursion Pharmaceuticals
MT
01/10RECURSION PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements and Exhib..
AQ
2021INSIDER SELL : Recursion Pharmaceuticals
MT
2021RECURSION PHARMACEUTICALS, INC.(NASD : RXRX) added to NASDAQ Biotechnology Index
CI
2021SVB Leerink Adjusts Recursion Pharmaceuticals' Price Target to $32 from $30, Keeps Outp..
MT
2021Roche, Genentech Join Recursion Pharmaceuticals to Advance Neuroscience, Oncology Medic..
MT
2021Recursion Pharmaceuticals Sets Drug-Discovery Pact With Roche, Genentech
DJ
2021Recursion Pharmaceuticals Signs Neuroscience, Oncology Collaboration Deal With Roche, G..
MT
2021RECURSION PHARMACEUTICALS : Announces Transformational Collaboration with Roche and Genent..
PU
2021RECURSION PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Financial St..
AQ
More news
Analyst Recommendations on RECURSION PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 12,0 M - -
Net income 2021 -176 M - -
Net cash 2021 318 M - -
P/E ratio 2021 -9,24x
Yield 2021 -
Capitalization 1 872 M 1 872 M -
EV / Sales 2021 130x
EV / Sales 2022 26,7x
Nbr of Employees 330
Free-Float -
Chart RECURSION PHARMACEUTICALS, INC.
Duration : Period :
Recursion Pharmaceuticals, Inc. Technical Analysis Chart | RXRX | US75629V1044 | MarketScreener
Technical analysis trends RECURSION PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 11,08 $
Average target price 32,67 $
Spread / Average Target 195%
EPS Revisions
Managers and Directors
Chistopher C. Gibson Chief Executive Officer & Director
Tina Larson Chief Operating Officer
Michael Secora Chief Financial Officer
Ramon Martin Chavez Márquez Independent Chairman
Benjamin Mabey Vice President-Software Engineering
Sector and Competitors
1st jan.Capi. (M$)
RECURSION PHARMACEUTICALS, INC.-35.32%1 872
GILEAD SCIENCES, INC.-7.26%84 470
REGENERON PHARMACEUTICALS-4.16%63 282
VERTEX PHARMACEUTICALS3.18%57 608
WUXI APPTEC CO., LTD.-12.95%47 873
BIONTECH SE-37.66%38 812